Derivative exercise or conversion — not an open-market buy.
Traded Jul 20, 2026 · Filed Jul 21, 2026
Johnson & Johnson's Global Corp Affairs sold $5.79M of Johnson & Johnson shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$5,792,686
Shares × reported transaction price
5 days after results of Jul 15, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $248.82 on Jul 20, 2026, 51% above its 52-week low and 7% below its high, after a 9% rise over the previous 30 trading days
52-week range $164.36 (Jul 21, 2025) to $267.24 (Jul 7, 2026), 82% of the way up, from 251 adjusted closes. 30 trading days earlier: $228.17 on Jun 4, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.9% | -2.4% | +6.3% |
| 30 days | +5.7% | +2.5% | +3.3% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Johnson & Johnson's WWC. Innovative Medicine sold $3.95M of Johnson & Johnson shares. Nobody planned it ahead of time.
Derivative exercise or conversion — not an open-market buy.